Korro Bio reports FY24 EPS ($9.37), consensus ($9.73)

Reports FY24 revenue $2.271M. “We executed on our key objectives in 2024 by initiating the Phase 1/2a REWRITE clinical study of KRRO-110 for AATD, announcing a collaboration with Novo Nordisk, and advancing multiple product candidates in our pipeline,” said Ram Aiyar, PhD, CEO and President of Korro. “KRRO-110 has best-in-class potential based on our preclinical data, and we are excited to potentially demonstrate this in PiZZ patients in the second half of 2025 with the interim data readout of REWRITE. We also anticipate announcing our second development candidate by the end of 2025. Our strategy of taking three development candidates in two tissue types with a single RNA-editing platform in the clinic by the end of 2027 will expand the possibilities of RNA editing, underscoring our commitment to progressing both our wholly owned and partnered programs.”